Rare Cancer Biotech, Major Shareholder and Executive Stake Liquidation After $2.5 Billion Acquisition

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN), a US biotech specializing in rare cancers, fully surrendered its roughly several-hundred-million-dollar stake—including just over 12% of its shares and associated warrants held by Access Industries–affiliate AI Day1 LLC—by tendering them to a buyout offer from a Servier subsidiary on April 9. Then, on April 23, Chief Legal Officer Adam Duvo and board member Natalie C. Hoss had their remaining equity compensation—common stock, stock options, and RSUs—cashed out at the merger consideration price of $21.50 per share. Hoss alone received about $1.2 million (mid-KRW 1 billion range) from her common-stock sale, leaving neither executive with any remaining equity in the company.

On April 23, French pharmaceutical firm Servier completed its acquisition of Day One, closing a $2.5 billion cash transaction—equivalent to just over KRW 3 trillion—at $21.50 per share. The deal adds the pediatric low-grade glioma therapy OJEMDA and a rare-cancer-focused clinical pipeline to Servier’s portfolio, and marks Day One’s delisting from Nasdaq as it transitions to private status.

Day One is a US biotech that commercialized OJEMDA—a targeted therapy for pediatric rare brain tumors with BRAF mutations, including low-grade glioma in children and adolescents—following the US FDA’s accelerated approval in 2024. The company maintains a pipeline specialized in pediatric and rare cancers.

As global pharmaceutical companies continue to acquire commercially staged oncology biotechs for multi-trillion-won deals to strengthen their pediatric and rare-cancer portfolios, Servier’s purchase of Day One stands out as a notable case of securing rare-cancer assets amid this ongoing oncology M&A trend.